Full Press Release Details
Protalix Appoints Mr. Zeev Bronfeld Interim Chairman of the Board of Directors
CARMIEL, Israel, March 9 Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX), announced today that
Mr. Eli Hurvitz is relinquishing his position as Chairman and member of the Board of Directors of
the Company in order to focus on recovering from a recently diagnosed illness. The Company s Board
of Directors has unanimously appointed Mr. Zeev Bronfeld, a longstanding member of the
Board of Directors, to serve as interim Chairman of the Board, effective immediately.
We are very thankful to have had Mr. Eli Hurvitz serve as our Chairman. He brought a wealth of
knowledge and expertise to Protalix that helped to grow the Company from a private research company
to a fully integrated biotechnology company, said Mr. Bronfeld. On behalf of everyone at
Protalix, we wish Eli a fast and full recovery and hope he returns to his position with Protalix
Mr. Bronfeld became the Company s first investor and director in 1996. As a seasoned healthcare
investor, Mr. Bronfeld brings vast experience in management and value building of biotechnology
companies to the Company. He is a co-founder of Biocell Ltd., an Israeli publicly traded
biotechnology holding company and has served as its Chief Executive Officer since 1986. Mr.
Bronfeld currently serves as a director of Biocell Ltd., D. Medical Industries Ltd., and Biomedix
Incubator Ltd., all of which are publicly-traded on the Tel Aviv Stock Exchange. Mr. Bronfeld is
also a director of Meitav Technological Incubator Ltd., Ecocycle Israel Ltd., Contipi Ltd.,
Nilimedix Ltd., G-Sense Ltd. and L.N. Innovative Technologies. Mr. Bronfeld holds a B.A. in
Economics from the Hebrew University.
Protalix is a biopharmaceutical company focused on the development and commercialization of
proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based
expression system. Protalix s ProCellEx presents a proprietary method for the expression of
recombinant proteins that the Company believes will allow for the industrial-scale production of
recombinant therapeutic proteins in an environment free of mammalian components and viruses.
Protalix is also advancing additional recombinant biopharmaceutical drug development programs.
Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol
Assessment with the FDA for Gaucher disease. In August 2009, the FDA granted orphan drug status
and fast track designation to taliglucerase alfa for the treatment of Gaucher disease and Protalix
filed a rolling NDA submission with the FDA in December 2009. In November 2009, Protalix granted
Pfizer Inc. exclusive, worldwide rights to develop and commercialize taliglucerase alfa for the
treatment of Gaucher disease, except in Israel. Protalix retained the right to commercialize
taliglucerase alfa in Israel.
Safe Harbor Statement:
To the extent that statements in this press release are not strictly historical, all such
statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private
Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to known and unknown risks and
uncertainties that may cause actual future experience and results to differ materially from the
statements made. These statements are based on our current beliefs and expectations as to such
future outcomes and are valid only as of the date hereof. We disclaim any obligation to update
this information except to the extent required by law.
The Trout Group, LLC
Telephone: 646-378-2927
Email: mnanus@troutgroup.com
BMC Communications Group, LLC
Telephone: 212-477-9007 x17
Email: brad@bmccommunications.com